ArticleScientific reports2023
A mathematical model for COVID-19 considering waning immunity, vaccination and control measures.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Use of the test-negative design to estimate the protective effect of a scalar immune measure: a simulation analysis.American journal of epidemiology · 2026Article
- Hybrid modeling and forecasting of COVID-19: integrating SEAIQHRD and GPR for improved predictions.BMC infectious diseases · 2026Article
- Evaluating voluntary care seeking effects on COVID-19 outcomes and health system costs.Scientific reports · 2025Article
- Studying Disease Reinfection Rates, Vaccine Efficacy, and the Timing of Vaccine Rollout in the Context of Infectious Diseases: A COVID-19 Case Study.International journal of environmental research and public health · 2025Article
- Evaluating the effectiveness of vaccination campaigns: Insights from unvaccinated mortality data.Infectious Disease Modelling · 2025Article
- Impact of exposure frequency on disease burden of the common cold - A mathematical modeling perspective.PloS one · 2025Article
- Kinetics of Viral Shedding for Outbreak Surveillance of Emerging Infectious Diseases: Modeling Approach to SARS-CoV-2 Alpha and Omicron Infection.JMIR public health and surveillance · 2024Article
- A stochastic approach for co-evolution process of virus and human immune system.Scientific reports · 2024Article
- An Epidemic Model with Infection Age and Vaccination Age Structure.Infectious disease reports · 2024Article
- Mathematical Modeling Evaluates How Vaccinations Affected the Course of COVID-19 Disease Progression.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work we define a modified SEIR model that accounts for the spread of infection during the latent period, infections from asymptomatic or pauci-symptomatic infected individuals, potential loss of acquired immunity, people's increasing awareness of social distancing and the use of vaccination as well as non-pharmaceutical interventions like social confinement. We estimate model parameters in three different scenarios-in Italy, where there is a growing number of cases and re-emergence of the epidemic, in India, where there are significant number of cases post confinement period and in Victoria, Australia where a re-emergence has been controlled with severe social confinement program. Our result shows the benefit of long term confinement of 50% or above population and extensive testing. With respect to loss of acquired immunity, our model suggests higher impact for Italy. We also show that a reasonably effective vaccine with mass vaccination program are successful measures in significantly controlling the size of infected population. We show that for a country like India, a reduction in contact rate by 50% compared to a reduction of 10% reduces death from 0.0268 to 0.0141% of population. Similarly, for a country like Italy we show that reducing contact rate by half can reduce a potential peak infection of 15% population to less than 1.5% of population, and potential deaths from 0.48 to 0.04%. With respect to vaccination, we show that even a 75% efficient vaccine administered to 50% population can reduce the peak number of infected population by nearly 50% in Italy. Similarly, for India, a 0.056% of population would die without vaccination, while 93.75% efficient vaccine given to 30% population would bring this down to 0.036% of population, and 93.75% efficient vaccine given to 70% population would bring this down to 0.034%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.